Merus NV MRUS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/17/24 EDT
43.91UNCH (UNCH)
Volume
7,321,791
Close
43.91quote price arrow down-1.11 (-2.47%)
Volume
486,819
52 week range
19.81 - 52.03
Loading...
  • Open45.06
  • Day High45.15
  • Day Low43.62
  • Prev Close45.02
  • 52 Week High52.03
  • 52 Week High Date03/01/24
  • 52 Week Low19.81
  • 52 Week Low Date10/30/23

Key Stats

  • Market Cap2.577B
  • Shares Out58.69M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.05
  • YTD % Change63.71

KEY STATS

  • Open45.06
  • Day High45.15
  • Day Low43.62
  • Prev Close45.02
  • 52 Week High52.03
  • 52 Week High Date03/01/24
  • 52 Week Low19.81
  • 52 Week Low Date10/30/23
  • Market Cap2.577B
  • Shares Out58.69M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.05
  • YTD % Change63.71

RATIOS/PROFITABILITY

  • EPS (TTM)-2.72
  • P/E (TTM)-16.12
  • Fwd P/E (NTM)-14.19
  • EBITDA (TTM)-164.045M
  • ROE (TTM)-52.79%
  • Revenue (TTM)38.337M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-390.36%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/05/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Merus NV

 

Profile

MORE
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor...
Anand Mehra M.D.
Non-Executive Independent Chairman of the Board
Sven Lundberg M.D.
President, Chief Executive Officer, Executive Director
Peter Silverman J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Gregory Perry
Chief Financial Officer
Address
Uppsalalaan 17, 3rd & 4th floor
Utrecht
3584 CT
Netherlands

Top Peers

SYMBOLLASTCHG%CHG
ARWR
Arrowhead Pharmaceuticals Inc
24.77-0.23-0.92%
CLDX
Celldex Therapeutics Inc
38.21-1.73-4.33%
MLTX
MoonLake Immunotherapeutics
39.75-1.11-2.72%
APGE
Apogee Therapeutics Inc
50.31-3.44-6.40%
JANX
Janux Therapeutics Inc
47.10-0.41-0.86%